European Cancer Therapies Market - Growth, Trends and Forecasts 2017 - 2022

  • ID: 4387336
  • Report
  • Region: Europe
  • 134 pages
  • Mordor Intelligence
1 of 3
The Europe market for Cancer therapy market has been estimated at USD 6.024 billion for the year 2014 and is projected to reach USD 12.54 billion by the end of 2020 at a CAGR of 13 % during the forecast period from 2014 to 2021. Cancer is a malignant growth caused by uncontrolled division of cells in a part of body. Cancer is the leading cause of death and the incidence rates are increasing annually. Due to this, demand for quality cancer treatments also has risen dramatically which is contributing to the growth of the market.

The end-users of this market are clinics, hospitals and research centers. Lung cancer, breast cancer, colorectal cancers, ovarian cancer, head and neck cancer, stomach cancer and liver cancer are some of the common cancers increasing the treatment options in Europe.

Increasing incidences of cancer, aging population, growing demand for advanced therapies, patent expiry of leading drugs, government initiatives and increasing public awareness about diseases and treatment options are the factors driving the growth of Europe market. On other hand, high prices of therapies, side-effects caused during treatment, change in reimbursement policies and stringent regulatory issues are the factors restraining the market growth.

The market for Cancer therapy in Europe is segmented based on the type of therapy which includes Chemotherapy (Marketed drugs and drugs in pipeline), Radiotherapy, Surgery, Hormone therapy, Targeted cancer therapy, Immunotherapy (Monoclonal antibodies, cancer vaccines and non-specific immunotherapy) and Combination therapy. Chemotherapy, Radiation therapy and Combinational therapy are increasingly available in European regions. However, chemotherapy is well established and largest segment of the therapeutics market.

Based on geography, Europe market is segmented into France, UK, Germany, Russia, Italy, Spain & Portugal, Scandinavia and BENELUX. Europe is the second largest region dominating the market, after North America. UK contributes a larger share to the European cancer therapeutics market.

Many players in this market are trying to expand their product portfolio in order to top the global market. While few companies are entering into the market by acquisitions, top companies are expanding their growth in this market by acquiring other companies. Few companies adopted product innovation and new product launches as its key business strategy to ensure its dominance in this market. Roche is developing biggest number of combinational therapies. Major companies discussed in the report are Roche, Merck, Bristol-Myers Squibb, Novartis, Celgene, Teva, Pfizer, Astra Zeneca, GlaxoSmithKline PLC, GPC Biotech AG, Genentech Inc., Osi Pharmaceuticals Inc. and Janssen.

Key Deliverables:

Market analysis for the Europe Cancer therapy Market, with region specific assessments and competition analysis on global and regional scales

Market definition along with the identification of key drivers and restraints

Identification of factors instrumental in changing the market scenarios, rising prospective opportunities, and identification of key companies that can influence this market on a global and regional scale

Extensively researched competitive landscape section with profiles of major companies along with their market shares

Identification and analysis of the macro and micro factors that affect the Europe Cancer therapy Market on both global and regional scales

A comprehensive list of key market players along with the analysis of their current strategic interests and key financial information

A wide-ranging knowledge and insights about the major players in this industry and the key strategies adopted by them to sustain and grow in the studied market

Insights on the major countries/regions in which this industry is blooming and to also identify the regions that are still untapped.
READ MORE
Note: Product cover images may vary from those shown
2 of 3
1. INTRODUCTION
2. EXECUTIVE SUMMARY
2.1 Cancer drug Market Review
2.2 Research Methodology
3. MARKET DYNAMICS
3.1 Market Drivers
3.1.1 Rise in Cancer Incidences and Access to modern Therapeutics
3.1.1 Population of Aged people
3.1.1 Efficiency and High Price Magnetize manufacturers
3.1.1 Innovations, Improvements and Approvals promote growth
3.2 Market Restraints
3.2.1 High price of therapies
3.2.2 Change in Reimbursement Policies
3.2.3 Challenges encountered in clinical trials
4. Types of Cancer
4.1 Blood Cancer
4.2 Bone Cancer
4.3 Brain Cancer
4.4 Breast Cancer
4.5 Digestive/ Gastrointestinal Cancer
4.6 Endocrine Cancer
4.7 Eye Cancer
4.8 Genitourinary Cancer
4.9 Gynaecologic Cancer
4.10 Head & Neck Cancers
4.11 Respiratory/Lung Cancer
4.12 Skin Cancer
5. Cancer Treatment Types
5.1 Surgery
5.2 Chemotherapy
5.3 Radiation Therapy
5.4 Targeted Therapy
5.5 Immunotherapy (Biologic Therapy)
5.6 Hormonal Therapy
5.7 Hyperthermia
5.8 Stem Cell Transplant
5.9 Other Therapies
6 CANCER THERAPY MARKET
6.1 Europe Market Trend
6.2 Market Size and Share Estimation
7. Market Segmentation
7.1 Targeted Cancer Therapeutics
7.1.1 Introduction
7.1.2 Targeted cancer therapy vs Chemotherapy
7.1.3 Targets for targeted cancer therapy
7.1.4 Types of targeted cancer therapies
7.1.4.1 Hormone therapies
7.1.4.2 Signal transduction inhibitors
7.1.4.3 Gene expression modulators
7.1.4.4 Apoptosis inducers
7.1.4.5 Angiogenesis inhibitors
7.1.4.6 Immunotherapies
7.1.4.7 Monoclonal antibodies
7.1.5 Limitations of targeted cancer therapy
7.1.6 Current and future analysis
7.1.7 List of selected targeted therapy drugs
7.1.8 Products in Pipeline
7.1.9 Major players in the market
7.1.9.1 Roche/ Genentech
7.1.9.1.1 Company Profile
7.1.9.1.2 Products in the market
7.1.9.1.3 Financial overview
7.1.9.2 Novartis
7.1.9.2.1 Company Profile
7.1.9.2.2 Products in the market
7.1.9.2.3 Financial overview
7.1.9.3 Bristol-Myers Squibb
7.1.9.3.1 Company Profile
7.1.9.3.2 Products in the market
7.1.9.3.3 Financial overview
7.2 Immunotherapy
7.2.1 Introduction of Immunotherapy
7.2.2 Types of cancer immunotherapies
7.2.2.1 Monoclonal antibodies
7.2.2.1.1 Naked monoclonal antibodies
7.2.2.1.2 Conjugated monoclonal antibodies
7.2.2.1.2.1 Radiolabeled antibodies
7.2.2.1.2.2 Chemolabeled antibodies
7.2.2.2 Cancer vaccines
7.2.2.2.1 Vaccines to help prevent cancer
7.2.2.2.2 Vaccines to help treat cancer
7.2.2.3 Non-specific immunotherapies
7.2.2.3.1 Interferons
7.2.2.3.2 Interleukins.
7.2.3 Current and Future analysis
7.2.4 Limitations of Immunotherapy
7.2.5 List of selected drugs
7.2.6 Major Players in the market
7.2.6.1 Dendreon
7.2.6.1.1 Company Profile
7.2.6.1.2 Products in the market
7.2.6.1.3 Financial overview
7.2.6.2 Galena Biopharma
7.2.6.2.1 Company Profile
7.2.6.2 .2 Products in the market
7.2.6.2 .3 Financial overview
7.2.6.3 NewLink Genetics
7.2.6.3.1 Company Profile
7.2.6.3.2 Products in the market
7.2.6.3.3 Financial overview
7.2.6.4 Peregrine Pharmaceuticals
7.2.6.4.1 Company Profile
7.2.6.4.2 Products in the market
7.2.6.4.3 Financial overview
7.2.6.5 Inovio Pharmaceuticals
7.2.6.5.1Company Profile
7.2.6.5.2Products in the market
7.2.6.5.3 Financial overview
7.3 Hormone Therapy
7.3.1 Introduction of Hormone therapy
7.3.2Aromatase Inhibitors
7.3.3 Selective Estrogen Receptor Modulators
7.3.4 Estrogen Receptors downregulators
7.3.5 Hormone therapy Vs HRT.
7.3.6 Forms of hormone therapy
7.3.6.1 Nasal spray
7.3.6.2 Pills or tablets, taken by mouth
7.3.6.3 Skin gel
7.3.6.4 Skin patches
7.3.6.5 Vaginal creams or vaginal tablets
7.3.6.6 Vaginal ring
7.3.7 Current and future analysis
7.3.8 Products in the current market
7.4 Chemotherapy
7.4.1 Introduction of chemotherapy
7.4.2 Types of agents
7.4.2.1 Alkylating agents
7.4.2.2 Anti-metabolites
7.4.2.3 Anti-microtubule agents
7.4.2.4 Topoisomerase inhibitors
7.4.2.5 Cytotoxic antibiotics
7.4.3 Current and future analysis
7.4.4 Products in market
7.4.5 Chemotherapy regimens
7.4.5.1 Breast Cancer
7.4.5.2 Hodgeking's Disease
7.4.5.3 Germ cell tumor
7.4.5.4 Stomach Cancer
7.4.5.5 Bladder cancer
7.4.5.6 Lung cancer
8 Market Segmentation , Based on Geography
8.1 Europe
8.1.1 Germany
8.1.2 France
8.1.3 Italy
8.1.4 Spain
8.1.5 Sweden
9. Competitive landscape
9.1 Introduction
9.2 New Product Launch
9.3 Strategic development
9.4 Mergers, Acquisitions
9.5 Market Share Analysis
10. Company Profiles
10.1 ASTRAZENECA PLC
10.2 CHUGAI PHARMACEUTICAL CO., LTD.
10.3 GENENTECH INC.
10.4 GLAXOSMITHKLINE PLC
10.5 GPC BIOTECH AG
10.6 OSI PHARMACEUTICALS, INC.
11. Appendix
11.1. Abbreviations
11.2. Sources
11.3. Bibliography
11.4. Disclaimer
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
Note: Product cover images may vary from those shown
Adroll
adroll